US EditionWeight loss jabs could almost halve risk of obesity-related cancers beyond slimming down, study suggests
- Researchers examined health records of 6,356 obese adults with type 2 diabetes who received either GLP-1 receptor agonist treatments or underwent bariatric surgery during the period from 2010 to 2018 in Israel.
- The study compared these patients, matched by age, sex, BMI, smoking status, and treatment time, to assess obesity-related cancer risk over about 7.5 years.
- Results showed similar rates of obesity-related cancers, predominantly postmenopausal breast, colorectal, and uterine cancers, occurred in both treatment groups despite greater weight loss in surgery patients.
- GLP-1 receptor agonists reduced obesity-related cancer risk by 41% beyond weight loss effects, possibly through mechanisms like inflammation reduction, according to co-lead authors Dr Yael Wolff Sagy and Professor Dror Dicker.
- As an observational study, these findings need confirmation in large randomized trials, with future research also required to evaluate effects of newer GLP-1 drugs and non-obesity-related cancer risks.
24 Articles
24 Articles
Sky News UK
WTX NewsWeight loss jabs could almost halve risk of obesity-related cancers beyond slimming down, study suggests
Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, according to the NHS.
GLP-1RAs show added protection against cancer beyond weight reduction
New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.
GLP-1 receptor agonists show anti-cancer benefits beyond weight loss
*Please mention the European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14) if using this research* New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.
The Independent
The Independent (US)Weight loss jabs could have surprise anti-cancer effect
Weight loss jabs are available on the NHS for people with a high BMI, or via private providers
Evening Standard
perspectivemedia.comWeight loss injections may have an anti-cancer effect ‘beyond weight loss’
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings
Coverage Details
Bias Distribution
- 40% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
